EDWARDS LIFESCIENCES OUTLINES GROWTH STRATEGY AT ANNUAL INVESTOR CONFERENCE
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
Edwards Lifesciences (EW) PT Lowered to $85 at Truist Securities
December 9, 2022 7:32 AM ESTTruist Securities analyst Richard Newitter lowered the price target on Edwards Lifesciences (NYSE: EW) to $85.00 (from $95.00) while maintaining a Buy rating.
The analyst commented, "While a planned CEO transition does add a new factor, EW's NYC I-Day is unlikely to sway the... More
